Tasigna is a relatively new drug developed by Novartis for the treatment of leukemia. Not long after Tasigna was released in the U.S., evidence emerged indicating that Tasigna could cause a dangerous condition called atherosclerosis (narrowing of the blood arteries to the heart).
Plaintiffs’ lawyers claim that Novartis knew or should have known about this dangerous side-effect, but failed to include a warning in the prescribing information.
Users of Tasigna who suffered vascular damage from this undisclosed side-effect may be entitled to compensation for their injuries. Novartis has already been sued in a growing number of Tasigna lawsuits and a new “class-action” MDL has been created for consolidated handling of the Tasigna cases.